Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/10011—Adenoviridae
  • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
  • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
  • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/10011—Adenoviridae
  • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
  • C12N2710/10351—Methods of production or purification of viral material
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol

Definitions

• the present invention relates to a method of maximizing production of a thermo-stable virus based on a cell culture temperature shift strategy which results in a substantial enhancement of thermal stable virus production.
• the manipulation of cell culture conditions calls for growing cells at a sub-optimal host cell growth temperature for a period of time prior to virus infection, by shifting the cell growth temperature down to a sub-optimal level for a period of time or by growing cells at a sub-optimal temperature for the entire multiple passages of cell expansion process from the inoculation of a cryopreserved ampule of cells, followed by shifting the temperature up to a higher level prior to, simultaneous to, or after virus infection of the host cells.
• This methodology results in a substantial increase in recoverable virus as compared with known temperature schemes for virus production within a host cell culture.
• adeno viruses are the adeno viruses.
• the adeno viruses are grouped within the family Adenovi ⁇ dae, which are split into the genus Aviadenovirus (birds) and Mastadenovirus (human, simian, bovine, equine, porcine, ovine, canine and opossum).
• a review of the family Adenoviridae can be found in Fundamental Biology, 3 rd Ed., Fields, B.N., Knipe, D.M., and Howley, P.M., Ed., at Chapter 30, pp.
• a replication incompetent virus (such as an E1/E3 deleted Ad5gag vector expressing a HTV gag transgene, as exemplified herein) requires a cell line which complements the deletions.
• any such cell line may be used to generate recombinant virus vectors, with preferred, but not limiting, cell lines including 293 cells and PER.C6TM cells.
• cell lines including 293 cells and PER.C6TM cells.
• numerous 1 st generation recombinant adenovirus vectors have been described in the literature (e.g., see Bett, et al., 1994, Proc. Natl. Acad. Sci. 91:8802-8806; WO 01/02607 and WO 02/22080).
• "Gutless" adenoviral vectors are a 2 nd generation adenoviral vector generally devoid of viral protein-coding sequences, frequently with viral proteins supplemented in trans by a helper virus (often an El -deleted adenovirus) grown with the helper-dependent (HD) adeno vector in a packaging cell line (e.g., PER.C6TM). Absent viral proteins, these viral vectors can, in the alternative, be supplemented in trans by a cell line and or "helper virus” capable of expressing the structural and functional adenoviral proteins necessary for successful replication, packaging and rescue.
• helper virus an El -deleted adenovirus
• HD helper-dependent adeno vector in a packaging cell line
• temperature is an important process parameter for both cell growth and virus production.
• the physiological temperature of 37°C has been shown to be optimal for growth of a majority of mammalian cell lines. Temperatures below 37°C historically are shown to reduce cell growth rate, overall cell metabolism, and specific product formation in mammalian cells (see, e.g., Moore, et al., 1997,
• the optimal temperature for virus production depends on the virus strain and the host cell line, but has most often been found to be below 37°C, including 34°C for herpes simplex virus (HSN) production in FL cell culture (Hoggan and Roizman, 1959, Virology 8:508-524), 32 to 34°C for myxoma virus (Ross and Sanders, 1979, J. Gen. Virol. 43:213-216), and 35°C for foot-and-mouth disease virus in suspension BHK 21 cell cultures (Capstick et al., 1967, J. Hyg. Camb.
• HSN herpes simplex virus
• the present invention addresses and meets these needs by disclosing an optimized cell culture and virus production process which defines optimal temperature ranges, resulting in an improved virus productivity as well as elimination of intra-batch productivity variations.
• the present invention relates to a method of maximizing production of a thermo-stable virus based on a cell culture temperature shift strategy which results in a substantial enhancement of thermal stable virus production.
• the manipulation of temperature within the cell culture/virus production process disclosed herein relies upon a temperature shift strategy whereby (1) the culture of host cells are shifted to a sub-optimal temperature for a period of time prior to virus infection or, (2) the host cell culture is inoculated and grown at a respective sub-optimal temperature, followed by a shift back to a more optimal growth temperature at or near the time of virus infection of the respective host cells.
• Adaptation of such a temperature shift strategy presents a simple yet effective method to substantially increase recoverable virus within a respective host cell / virus production scheme without the need to further manipulate other culture and/or medium conditions within an established host cell/virus production scheme.
• thermo-stable viruses such as members of the Adenoviridae family (including all known adenovirus serotypes, and recombinant virus generated from such an adenovirus serotype, including any first or second generation recombinant adenovirus vector known in the art) and members of the Picomavirus family (e.g., poliovirus, rhinovirus, hepatitis A virus, Foot and Mouth Disease Virus).
• a preferred virus is any serotype of adenovirus, and especially preferred is any recombinant 1 st or 2 nd generation recombinant adenovirus vector containing at least one heterologous transgene (see, e.g., e.g., see Bett, et al., 1994, Proc. Natl. Acad. Sci. 91:8802-8806; WO 01/02607 and WO 02/22080, the three publications hereby incorporated by reference).
• the present invention relies in part on a temperature shift strategy for cell growth which comprises reducing the culture temperature to a sub-optimal level for a period of time prior to virus infection or growing cells at a sub- optimal level for the entire cell expansion process including one or more than one passages of cell growth from cryopreserved cells, followed by a shift up to or near the physiological temperature for production of that particular virus prior to, simultaneous to, or after virus infection of the host cells.
• Various parameters which may be further manipulated in relation to the temperature shift methodology disclosed herein and which fall within the scope of the present invention include but are not necessarily limited to (1) altering the range of the shift to sub-optimal culture conditions; (2) altering the length of time of host cell culture at a sub-optimal temperature; and, (3) coordinating the time of infecting the cell culture with virus with a return to an optimal cell culture condition at or near the known physiological optimum for the respective host cell/virus system, this temperature shift occurring at a reasonable point in time surrounding the time of virus seeding, namely prior to virus infection of the cell culture, simultaneous to virus infection or at a point in time subsequent to virus infection of the cell culture.
• One embodiment of the present invention relates to a cell culture temperature shift strategy to enhance virus production; wherein the temperature shift comprises a lowering of the cell culture temperature to a level sub-optimal for cell growth for a period of time prior to infecting the cells with the respective virus, such as a recombinant adenovirus vector.
• the temperature is again shifted to the physiological cell culture temperature, or a temperature which approximates the physiological culture temperature; the combination of cell exposure at the low temperature and the shift upwards reflecting a physiologically optimum practice for virus production.
• Another embodiment of the present invention relates to a cell culture temperature shift strategy to enhance virus production; wherein the temperature shift comprises a lowering of the cell culture temperature to a level sub-optimal for cell growth from the time of inoculating the cell culture with host cells from cryopreserved cells and continuing growth of the cell culture at a sub-optimal temperature for one or more than one passages until a temperature shift to an optimal temperature, which should occur at a reasonable point in time surrounding the time of virus seeding, namely prior to virus infection of the cell culture, simultaneous to virus infection or at a point in time subsequent to virus infection of the cell culture.
• the present invention relates to a method of producing virus which comprises inoculating and culturing host cells in an appropriate medium at a temperature below a physiological optimum for host cell growth, infecting the host cells with a virus, resulting in virus-infected host cells, culturing the virus-infected host cells at or near a physiologically optimum temperature for producing virus, harvesting and lysing host cells, and then purifying virus away from the harvested, lysed host cells, resulting in a purified virus product.
• a specific embodiment of the present invention relates to a method of producing virus which comprises inoculating and culturing host cells in an appropriate medium at a temperature at or near a physiological optimum for host cell growth, shifting the temperature of the host cell culture to a temperature below a physiological optimum for host cell growth, infecting the host cells with a virus, resulting in virus- infected host cells, culturing the virus-infected host cells at or near a physiologically optimum temperature for producing virus, harvesting and lysing host cells and purifying virus away from the harvested, lysed host cells, which results in a purified virus product.
• the time frame for a shift to a suboptimal temperature is preferably from about 4 hours to the entire pre-infection culture period (including from the time of inoculating the culture media with the host cells via inoculation of a cryopreserved ampule of cells) prior to the infection step; including but not limited to an initial culture inoculation at a suboptimal temperature, one to several cell passages at a suboptimal temperature, followed by a temperature shift up to a physiologically optimum temperature for virus infection and production.
• Preferable pre- and post-infection cell culture temperatures include but are not limited to a range of from about 31°C to 35°C for suboptimal cell growth s and from about 35°C to 38°C as a physiological optimum range for any culture period before (pre-infection) or after (post-infection) infection of the host cell culture with a virus seed stock. It is an object of the present invention to provide for a simple yet effective methodology for enhancing virus production in an established host cell / virus production culture system by incorporating a temperature scheme as disclosed herein for cell growth and virus infection.
• Figure 1 shows a schematic design of multiple passages of PER.C6TM cells and adenovirus infection at temperatures in roller bottles under serum-free conditions.
• Figure 2A and Figure 2B show viable cell concentrations of adenovirus infected PER.C6TM cells cultivated at temperatures of 31, 33, 35, 37, and 39°C: A.
• Group I with cells grown at 37°C prior to virus infection; B. Group II with cells grown at 33°C for 8 days prior to virus infection.
• Figure 3 A and 3B show viabilities of adenovirus infected PER.C6TM cells cultivated in at temperatures of 31, 33, 35, 37, and 39°C: A. Group I with cells grown at 37°C prior to virus infection; B. Group II with cells grown at 33°C for 8 days prior to virus infection.
• Figure 4A, 4B and 4C shows adenovirus replication kinetics and effects of culture temperature on virus productivity in PER.C6TM cultures at temperatures of 31, 33, 35, 37, and 39°C: A. intracellular virus productivity in Group I with cells grown at
• Figure 5 shows the experimental design with similarities to that in Figure 1, namely to measure the effect of the length of time at a "sub-optimal" temperature has on Ad5gag virus production.
• Figure 6 shows virus production under different temperature schemes from the study described in Figure 5.
• the present invention relates to a method of maximizing the production of a virus which is relatively thermo-stable under culture conditions, typically any non- enveloped virus, such as adeno viruses, parvo viruses, reoviruses, and/or picornaviruses.
• a virus which is relatively thermo-stable under culture conditions
• any non- enveloped virus such as adeno viruses, parvo viruses, reoviruses, and/or picornaviruses.
• cell growth in culture is typically conducted at the physiological temperature of 37°C and virus propagation is conducted either at the same temperature as cell growth or shifted downward to a lower temperature.
• the basis for such a production strategy has been that culture at the physiological temperature allows optimal cell growth but the optimal temperature for the production of many viruses is usually lower due to improved productivity and stability.
• the present invention is based on a counter intuitive approach involving cell culture/virus production temperature ranges which result in a substantial enhancement of thermal stable virus production.
• the present invention relates to a cell culture/virus production temperature shift strategy whereby culture of host cells are shifted to a sub-optimal culture temperature for a period of time prior to virus infection or cells are grown at a sub-optimal level for the entire cell expansion process including one or more than one passages of cell growth from cryopreserved cells, followed by a shift back to a more optimal temperature for virus production.
• Production of a recombinant adenovirus serotype 5 encoding a HIV gag transgene (Ad5gag) is exemplified herein.
• the present invention relates to a method of maximizing production of a thermo-stable virus based on a cell culture temperature shift strategy which results in a substantial enhancement of thermal stable virus production.
• the manipulation of temperature within the cell culture/virus production process disclosed herein relies upon a temperature shift strategy whereby (1) the culture of host cells are shifted to a sub-optimal temperature for a period of time prior to virus infection or, (2) the host cell culture is inoculated and grown at a respective sub-optimal temperature, followed by a shift back to a more optimal growth temperature at or near the time of virus infection of the respective host cells.
• Adaptation of such a temperature shift strategy presents a simple yet effective method to substantially increase recoverable virus within a respective host cell/virus production scheme without the need to further manipulate other culture and/or media conditions within an established host cell/virus production scheme.
• thermo-stable viruses regardless of the respective host cell/virus combination.
• the artisan may, with the present teachings in hand, adapt and optimize a temperature shift strategy which results in the highest possible increase in virus production.
• alter or manipulate culture conditions, media components and other such steps or methods which are known to the artisan which may be used in combination with a temperature shift strategy.
• Such parameters include but are not limited to altering the range of the shift to sub-optimal culture conditions (e.g., a cell culture shift from 37°C to 33°C and back to 37°C vs.
• the length of time of host cell culture at a sub-optimal temperature e.g., from the time of inoculation, 1 day, 4 days, 20 days etc.
• a coordination of virus infection with a return to an optimal cell culture conditions e.g., post-infection, at the time of infection, or at a specific time prior to the virus infection.
• incorporation of a temperature shift strategy will effectively allow for a substantial increase in virus production versus the utilization of those same parameters which omit a temperature shift cell culture strategy.
• the temperature shift methodology as disclosed herein will be especially useful in increasing virus production over and above the production levels which exist for a respective host cell/virus system.
• the present invention relates to a cell culture temperature shift strategy to enhance virus production; wherein the temperature shift comprises a lowering of the cell culture temperature to a sub-optimal level for a period of time prior to contacting the cells with the respective virus, such as a recombinant adenovirus vector.
• the temperature is again shifted to the physiological cell culture temperature, or a temperature which approximates the physiological culture temperature.
• production of a recombinant adenovirus vector is optimized using a temperature shift strategy.
• Host cells are grown at the optimal growth temperature range from about 35 -38°C, more preferably at about 36-38°C, and especially at 37°C at early passages to allow rapid expansion of cell numbers for large scale production, which reduces the duration of the batch cycle.
• the cell growth temperature is then shifted down to a sub-optimal temperature within a range from about 31°C to about 35°C (e.g., 33°C) and maintained for up to several days prior to the virus infection. After the virus infection, the temperature is shifted up to into the 35-38°C range to maximize the virus productivity. This temperature shift strategy resulted in a significant enhancement (2-3 fold in roller bottles and ca.
• the invention is especially related to the increased production of all adenovirus serotypes using El -transformed mammalian cell lines (293, PER.C6, etc.) in all types of culture vessels (T-flasks, roller bottles, Nunc Cell Factories, Cell Cubes, Wave bioreactor, spinner flask, shaker flask, stirred tank bioreactors, etc.) where temperature control is implemented. Therefore, as noted above, the present invention relies in part on a temperature shift strategy for cell growth which comprises reducing the culture temperature to a sub-optimal level for a period of time prior to virus seeding, followed by a return to or near the physiological temperature for production of that particular virus prior to, simultaneous to, or after virus infection of host cells.
• a temperature shift strategy for cell growth comprises reducing the culture temperature to a sub-optimal level for a period of time prior to virus seeding, followed by a return to or near the physiological temperature for production of that particular virus prior to, simultaneous to, or after virus infection of host cells.
• Various parameters which may be further manipulated in relation to the temperature shift methodology disclosed herein and which fall within the scope of the present invention include but are not necessarily limited to (1) altering the range of the shift to sub- optimal culture conditions; (2) altering the length of time of host cell culture at a sub- optimal temperature; and (3) coordinating the time of infecting the cell culture with virus with a return to an optimal cell culture condition at or near the known physiological optimum for the respective host cell/virus system, this temperature shift occurring at a reasonable point in time surrounding the time of virus seeding, namely prior to virus infection of the cell culture, simultaneous to virus infection or at a point in time subsequent to virus infection of the cell culture.
• the cell growth temperature is first shifted from an optimal physiological temperature (e.g., from about 35°C to about 38°C) to a temperature at or below 35°C for a period of time and then returned to culture at a physiologically optimal temperature at or near the time of virus infection of the cell culture.
• an optimal physiological temperature e.g., from about 35°C to about 38°C
• This regime results in an effective increase in virus production upon infection and return to culture conditions at optimal levels.
• any "suboptimal" temperature at or below 35°C is contemplated (with ranges from 31°C to 35°C, preferably 31°C to 34°C, and most preferably from about 31°C to about 33°C, with a higher range of 33°C to 35°C still being useful to the artisan) to practice the invention, as long as the "suboptimal" cell growth temperature supports reasonable cell growth and the optimal temperature for cell culture growth is from about 35°C to about 38°C (again, with about 36-38°C and then 36.5 to 37°C representing especially presferred ranges) and as long as there is an increase of temperature from the cell growth to virus infection.
• a preferred sub-optimal temperature range is from 31°C to 35°C, with a more preferred range from 31°C to 34°C, with sub-ranges of 31°C to 33°C and/or 33°C to 35°C being useful to the artisan.
• a preferable temperature shift strategy is one which effectively minimizes duration of cell expansion from a vial to large productions scale: cells are expanded at the physiological temperature of 37°C and shifted to the sub-optimal temperature for a a specific time, usually for at least 24 hours prior to the virus infection, with a return to the temperature of cell growth (such as 37°C) or slightly lower, depending upon the respective host cell and/or virus).
• an embodiment of the present invention relates to the period of time which the culture is subjected to sub-optimal growth conditions.
• the time period can range anywhere from several hours, to several passages (multiple days), to entire cell expansion period inoculating the initial culture from a frozen vial containing a stock of host cells. Included in the scope of the present invention is a scenario, and all in between, whereby the culture is initially inoculated at the sub-optimal temperature and kept at this lower temperature until seeding with the virus stock.
• the host cell for use in the temperature shift protocol comprising the present invention may be any mammalian cell line which supports replication of the respective thermo-stable virus, especially any host cell line known in the art which will support infection and replication of a 1 st or 2 nd generation adenovirus vector.
• a preferred host cell is a host cell line which supports infection and replication of an El and/or and E1/E3 deleted recombinant adenovirus.
• a replication-incompetent virus such an Ad5gag, as exemplified herein
• any such cell line may be used to generate recombinant virus, with preferred, but not limiting, cell lines including 293 cells, PER.C6TM cells, 911 cells from a human embryonic retinal cell line (Fallaux et al. 1996, Human Gene Therapy 1: 215-222); El -transformed amniocytes (Schiedner et al. 2000, Human Gene Therapy 11:2105-2116); an El -transformed A549 cell line for a human lung carcinoma (Imler et al. 1996, Gene Therapy 3:75-84) and GH329: HeLa (Gao et al. 2000, Human Gene Therapy 11: 213- 219).
• cell lines including 293 cells, PER.C6TM cells, 911 cells from a human embryonic retinal cell line (Fallaux et al. 1996, Human Gene Therapy 1: 215-222); El -transformed amniocytes (Schiedner et al. 2000, Human Gene Therapy 11:2105-2116); an El -transformed A549
• Such a cell line is transformed to support replication and packaging of a respective recombinant adenovirus, such as an El or E1/E3 deleted recombinant adenovirus.
• Additional cell lines which may be utilized in the present invention are again cell lines which have been adapted to act as host cells for a particular thermostable virus. It is preferable that the cell line be a continuous cell line and more preferable that the source of the cultured cells originate from a non-neoplastic tissue. It is also preferable that the source be mammalian, most likely from a primate origin, and especially of human origin.
• a preferred cell line is a cell line which is useful for the propagation of an Ad El or E1/E3 deleted recombinant virus; a recombinant virus which compliment El -deleted adenovirus vector included cell lines transfected with the gene encoding Ad El which have been selected for this transformed phenotype, such as 293 cells (epithelial cells from human kidney) and PER.C6TM (human embryonic retinoblasts).
• Other cell types include but are not limited to HeLa cells, A549 cells, KB cells, CKT1 cells, NIH/sT3 cells, Vero cells, Chinese Hamster Ovary (CHO) cells, or any eukaryotic cells which support the adenovirus life cycle.
• the culture be a suspension culture; a suspension culture which is maintained in a suitable medium which supports cell growth, virus infection and virus production.
• a suspension culture is well known in the art and, again, may be modified in any number of ways known to the artisan without effecting a useful incorporation of a temperature shift strategy to increase virus production.
• the culture medium can be subjected to various growth conditions which are suitable for virus production, including but not limited to batch, fed-batch or continuous perfusion operations to introduce fresh medium into the culture medium.
• the culture medium can be any suitable medium for maintaining the cells and permitting the propagation of the respective virus. Numerous examples of media suitable for use in the practice of the present invention, and the principles to generate modified or new suitable media, are widely known in the art.
• serum-based media and Chapter 9 (serum-free media) from Culture of Animal Cells: A Manual of Basic Technique; Ed. Freshen, RI, 2000, Wiley-Lisps, pp. 89-104 and 105-120, respectively.
• serum-based or serum free media will be manipulated to enhance growth of the respective cell line in culture, with a potential for inclusion of any of the following: a selection of secreted cellular proteins, diffusable nutrients, amino acids, organic and inorganic salts, vitamins, trace metals, sugars, and lipids as well as perhaps other compounds such as growth promoting substances (e.g., cytokines).
• cytokines growth promoting substances
• a preferable medium used in the context of the present invention is a defined medium, such as the medium exemplified herein as Ex-Cell 525 medium (from JRH Biosciences, [http//www.jhrbio.com]) and 293 SFM II medium (from Invitrogen). It is also desirable that such media are supplemented with glutamine, as disclosed herein.
• the virus types which are amenable to the temperature shift strategy of the present invention are preferably from two virus families that are non-enveloped DNA virus that infect human cells.
• viruses are the Adenoviridae family (including all known adenovirus serotypes, and recombinant virus generated from such an adenovirus serotype) and members of the Picomavirus family (e.g., poliovirus, rhinovirus, hepatitis A virus, Foot and Mouth Disease Vims).
• An adenovirus 5 serotype a member of the Adenoviridae family, is exemplified herein.
• the term "vims" as used herein is meant to cover any vims which is amenable to completing its replication cycle in the mammalian cell line of choice.
• this term is certainly meant to include wild type vims, any genetically modified vims such as an attenuated vims, or more likely a recombinant vims vector which may be a development candidate for a potential gene therapy and/or DNA vaccination application.
• Such programs have created a need for large scale manufacture and purification of clinical-grade vims.
• a preferred recombinant vims which is amenable to the improved cell culture/vims production parameters disclosed herein are a family of viruses known as the adeno vimses.
• the adeno vimses are grouped within the family Adenoviridae, which are split into the genus Aviadenovirus (birds) and Mastadenovirus (human, simian, bovine, equine, porcine, ovine, canine and opossum).
• Adenoviras are well known in the art and are subject to many reviews, such as can be found in Fundamental Biology, 3 rd Ed., Fields, B.N., Knipe, D.M., and Howley, P.M., Ed., at Chapter 30, pp. 979-1016 (1996), which is hereby incorporated by reference.
• adenoviras Of specific interest in gene vaccination and/or gene therapy applications is the use of a first generation replication incompetent adenoviras, crippled by El and/or E3 gene deletions, based on any of a number of adenoviras serotypes, such as serotype 5 of adenovirus.
• An additional type of vector is referred to as a 2 nd generation adenovims vector, and commonly includes a class of adenoviras vectors including "gutless" adenoviras vectors.
• Gutless adenoviral vectors are adenoviral vectors generally devoid of viral protein-coding sequences, frequently with viral proteins supplemented in trans by a helper virus (often an El -deleted adenovirus) grown with the HD adenovector in a packaging cell line (e.g., PER.C6TM). Absent viral proteins these viral vectors can, in the alternative, be supplemented in trans by a cell line capable of expressing the structural and functional adenoviral proteins necessary for successful replication, packaging and rescue.
• the only cis elements generally present on the HD vector are the packaging signal and the inverted terminal repeats (ITRs).
• the Ad virion is roughly at least 75% of the wild-type genome length.
• the Ad virion has been reported to essentially exhibit a lower packaging limit of approximately 75% of the wild-type genome length; see Parks & Graham, 1997 J. Virology 71(4):3293-3298.
• Adenoviral vector genomes smaller than 27.7 kb were found to package inefficiently and frequently undergo rearrangement.
• Adenoviras has a broad cell tropism including professional antigen presenting cells such as macrophages and dendritic cells, can infect (if not replicate in) cells from most animal species, and can be produced in large quantities in appropriate human cell lines designed to provide the El gene product in trans.
• PER.C6TM cells grown at 33 and 37°C were infected with a first generation adenoviras vector expressing HIV-1 gag at temperatures of 31, 33, 35, 37, and 39°C for virus production.
• the effects of temperature on the infected cell metabolism and adenoviras production were studied. It was observed that PER.C6TM cell growth became much more sensitive to culture temperature post adenoviras infection ( Figure 2 A and 2B in Example 1). Even at low temperatures, PER.C6 cells still grew well, albeit at a lower rate and maintained high viability at low temperatures.
• the temperature shift strategy disclosed herein can be easily implemented at any production scale by controlling temperature at different levels during the process. At large scale production, it is perceived that cell growth temperature during early cell expansion prior to the cell growth and viras infection in the large scale production can be set at the optimal physical temperature to achieve the fastest cell expansion for reduction of batch cell duration.
• the inventors have shown that a downward shift in temperature during pre-infection cell culture (e.g., such as seven to sixteen days prior to the planned virus infection), the temperature for cell growth can be shifted down to 31-35°C, more preferably from 31°C to 34°C, with sub- ranges of 31°C to 33°C and/or 33°C to 35°C remaining very useful, depending upon the repsective cell culture conditions (this could occur in the seeding vessel for the final production vessel and the final production vessel).
• the temperature is shifted up to 35-38°C, preferably from 36-38°C and most preferably from 36-37°C to achieve optimal viras production, as exemplified in the following non-limiting examples. These non-limiting Examples are presented to better illustrate the invention.
• Cell Line and Maintenance - PER.C6TM cells (Fallaux et al., 1998, Human Gene Therapy 9:1909-1917, see also U.S. Patent No. 5,994,128), a human embryonic retinoblast cell line licensed from Cracell (Leiden, The Netherlands), were derived by transfecting human embryonic retinoblast cells with an adenoviras type 5 El gene using a phosphoglyceratekinase promoter. The El gene expression confers immortalization on the cells and allows retention of the El(+) genotype in the absence of a selective marker.
• the cells were adapted to suspension culture, and routinely maintained in EX-CellTM 525 serum-free medium (JRH Biosciences, Lenexa KS) supplemented with 4 mM L-glutamine (Mediatech Inc., Hemdon VA), in roller bottles at 37°C and 5% CO 2 /95% air overlay.
• EX-CellTM 525 serum-free medium JRH Biosciences, Lenexa KS
• 4 mM L-glutamine Mediatech Inc., Hemdon VA
• the two roller bottles from each temperature groups were pooled to plant two new roller bottles and incubated at the respective temperatures for a second 3 -day passage.
• the cells from the 33 and 37°C groups were selected to passage a third time in 5 roller bottles per group for two days, followed by viras infection (See Figure 1).
• the two groups of five roller bottles derived from cells grown at 37 and 33 °C prior to the infection are designated as Group I and LI, respectively.
• Virus Seed Stock - A first generation adenoviras type 5 vector (El and E3 deleted) expressing the p55 gag transgene from HJN-1 (see WO 01/02607), was amplified in PER.C6TM cells.
• Temperature Monitoring and Control were place in water-jacketed incubators (Forma Scientific, Marietta OH) and a 37 °C warm room (Environmental Specialties, Raleigh ⁇ C).
• the incubators and warm room were adjusted to their target temperature set-points. Temperature mappings of the incubators and warm room were carried out during this period to confirm stability of temperature control.
• Six bottle positions were defined on roller apparatus in each of the incubators and the warm room. Temperature probes were inserted through holes in the roller bottle caps, with the bottles in place and rotating during measurement. These measures ensured the accuracy of the culture temperature for the study.
• Viral particle (VP) concentrations were measured by anion exchange HPLC (AEX assay), using a technique adapted from Shabram et al. (1997, Human Gene Therapy 8:453-465). The coefficient of variation for the anion exchange HPLC assay is typically less than 10%.
• a quantitative PCR based potency assay was employed to estimate the virus infectivity. Viras samples were used to infect 293 monolayer cultures in 96 wells. The viral DNA was extracted from each well at 24 hours post infection and quantified by a PCR method. Viras infectivity was estimated from a standard virus stock titered by the traditional TCID 5 0 assay.
• the virus particle concentrations in the cell pellets were normalized on a per cell basis as shown in Figure 4 ( Figure 4A - Group I; Figure 4B -Group H).
• Figure 4A the highest vims concentration in the cell pellets occurred at 37°C on day 2 post infection, suggesting that the viras replication rate was the highest at this temperature. Deviation to either side of this optimal temperature resulted in slower viras replication.
• intracellular viras concentration measured from the cell pellets seemed to have peaked earlier at higher temperatures.
• vims concentration in the cell pellets decreased at both 37 and 39°C. The reduced concentration was presumably a result of release of intracellular virions into the culture medium as cell viability decreased rapidly and cell lysis occurred.
• Group H the maximum intracellular virus concentration occurred at 37°C on day 2, at 35°C on day 3, and at 33°C on day 4, which is exactly the same as Group I. Peak intracellular concentration occurred on day 2 at 37 to 39°C, on day 3 at 33 to 35°C, and on day 4 at 31°C, which is also the same as Group I.
• the highest intracellular vims concentration occurred at 37°C on day 2 in Group II versus 35°C on day 3 in Group I.
• vims titers in Group II were 60% to 200% higher than in Group I. The differences were significantly larger at high temperatures. Differences between the two groups became smaller on day 3 and 4 but remained significant.
• the viras concentrations in the supematants were usually below the detection limit of the HPLC assay. Hence, a more sensitive infectivity assay was employed to measure this viras.
• Supernatant and cell pellet samples were measured head-to-head in the same assay in order to estimate the relative distribution of intracellular and extracellular virases.
• a significant amount of viras was released into the culture medium, especially at the late stage of viras replication when the cell viability was significantly reduced.
• EXAMPLE 2 Effect of Passage Time at Sub-Optimal Temperature on Virus Production Materials and Methods are essentially as described in Example 1. Briefly, Figure 5 summarizes the experimental design. Two bioreactors were inoculated with PER.C6 ® cells in 293 SFM II (Invitrogen, Grand Island, NY) semm-free medium supplemented with 6 mM L-glutamine (Biowhittaker Inc., Walkersville, MD) at 33.0 and 36.5°C. Cells were grown to ⁇ 2.5xl0 6 cells/ml and diluted in new bioreactors at the appropriate temperature. The temperature control scheme for each vessel is depicted in Figure 5, using 33.0°C "temperature shifts" ranging from 2 passages to 4 hours.
• the cells were infected with a replication-defective adenoviras encoding a FflV-1 gag transgene using a multiplicity of infection of 70 viral particles per viable cell.
• the temperature of all reactors was changed to 36.5°C immediately after infection.
• Viral concentration at 48 hours post infection (hpi) from supernatant and Triton-XlOO lysed whole broth samples (TL) containing both intracellular and extracellular viras was determined from HPLC assay daily.
• the vims bulk was then harvested by addition of a cell lysis buffer to release the remaining intracellular viras into the supernatant or by releasing intracellular viras using mechanical shear.
• Example 2 The resulted whole broth viras bulk was then further purified through multiple steps for the removal of cellular debris, host cell proteins and DNA, unpacked viral proteins and DNA, and other impurities.
• This example reiterates the results presented in Example 1, namely that studies in both roller bottles and 2L bioreactors indicate that controlling the temperature at 33.0°C during cell growth (for two passages) and at 37.0°C during infection enhanced viras production. Cell growth at 33.0°C is slower (doubling time -50 hr) than at 36.5°C (doubling time -30 hr). This results in an increase in total batch time from -12 days in bioreactors to -17 days, which lowers the time-specific viras production of a factory. It will be incumbent upon the skilled artisan to optimize the respective system such that optimal virus production is generated from a "sub- optimal" temperature passage while maintaining the enhanced virus production seen in previous experiments.
• Figure 6 shows virus production under different temperature control schemes, namely differing time periods at a sub-optimal temperature prior to vims seeding and raising the culture temperature back to a physiological optimum. These data show that a temperature shift of a few hours does not provide optimal enhancement of the viras productivity. The length of the "sub-optimal cell growth" at a reduced temperature can be further optimized to minimize the length of the production process. The data are consistent with the results obtained in roller bottles as described in Example 1. A 2-3 fold enhancement in viras productivity is obtained with the temperature shift strategy for sub-optimal incubation times ranging from 7 to 16 days as compared to the 36.5°C control.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Wood Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Biomedical Technology (AREA)
• Virology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=28791896

Family Applications (1)

Country Status (9)

Cited By (2)

Families Citing this family (2)

Citations (1)

Family Cites Families (5)

• 2003
  • 2003-03-27 EP EP03746051A patent/EP1492891B1/en not_active Expired - Lifetime
  • 2003-03-27 CA CA002478901A patent/CA2478901A1/en not_active Abandoned
  • 2003-03-27 AU AU2003226012A patent/AU2003226012B2/en not_active Ceased
  • 2003-03-27 JP JP2003582315A patent/JP4413012B2/ja not_active Expired - Fee Related
  • 2003-03-27 WO PCT/US2003/009269 patent/WO2003085138A1/en not_active Ceased
  • 2003-03-27 US US10/509,293 patent/US7344873B2/en not_active Expired - Fee Related
  • 2003-03-27 DE DE60319210T patent/DE60319210T2/de not_active Expired - Lifetime
  • 2003-03-27 ES ES03746051T patent/ES2299715T3/es not_active Expired - Lifetime
  • 2003-03-27 AT AT03746051T patent/ATE386824T1/de not_active IP Right Cessation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events